Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical innovator developing targeted therapies for oncology and rare diseases through advanced protein engineering. This dedicated news hub provides investors and industry observers with comprehensive access to official corporate communications and verified developments.
Our curated collection features INBX's latest press releases, regulatory filings, and clinical trial updates. Track progress across therapeutic programs including multivalent biologics and optimized antibody candidates designed through the company's proprietary modular platforms. Stay informed about strategic partnerships, research milestones, and financial disclosures that shape INBX's position in biopharmaceutical innovation.
Key updates include clinical development timelines, intellectual property advancements, and collaborative research initiatives. All content is sourced directly from company filings and authorized statements to ensure reliability. Bookmark this page for streamlined access to INBX's evolving pipeline and corporate announcements, presented with neutral analysis suitable for both institutional and individual investors.
Inhibrx, Inc. (NASDAQ: INBX) reported its financial results for Q4 and fiscal year 2022, showing significant increases in cash and cash equivalents, totaling $273.9 million, up from $131.3 million in 2021. R&D expenses rose to $30.5 million in Q4, compared to $18.6 million in the previous year, and net loss widened to $40.9 million or $0.95 per share. Key clinical updates include the initiation of INBRX-101's trial for Alpha-1 Antitrypsin Deficiency expected in April 2023 and promising results from INBRX-105. Despite increased operational costs, the company remains focused on advancing its clinical pipeline.
Inhibrx, Inc. (NASDAQ: INBX) and NorthStar Medical Radioisotopes have announced a collaboration to develop innovative radiopharmaceuticals targeting cancer treatment. This partnership leverages Inhibrx's optimized single-domain antibodies for targeted alpha therapies and NorthStar’s capacity as a supplier of non-carrier added actinium-225 (Ac-225) and copper-67 (Cu-67). The collaboration aims to enhance the efficacy of targeted therapies while ensuring sufficient supply for clinical and commercial use.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the 5th Annual HealthCONx Conference on November 30 at 8:45 a.m. PT. This virtual investor conference will include a live webcast of the presentation, available for at least 60 days on Inhibrx's investor website.
As a clinical-stage biopharmaceutical company, Inhibrx focuses on therapeutics for oncology and rare diseases, employing innovative protein engineering techniques. To learn more, visit www.inhibrx.com.
Inhibrx, Inc. (Nasdaq: INBX) reported updated efficacy and safety results from its Phase 1 trial of INBRX-109 for treating chondrosarcoma. Among 33 evaluable patients, the disease control rate was 87.9%, with 14 patients showing clinical benefits lasting over 6 months. The treatment exhibited a median progression-free survival of 7.6 months, with minimal adverse events. INBRX-109 has received Fast Track and orphan drug designations from FDA, highlighting its significance in treating this rare cancer.
On November 7, 2022, Inhibrx, Inc. (Nasdaq: INBX) reported its third quarter 2022 financial results, revealing a net loss of $35.3 million, or $0.90 per share, compared to a net loss of $20.6 million, or $0.54 per share in Q3 2021. Cash and equivalents stood at $146.1 million as of September 30, 2022, significantly up from $131.3 million at the end of 2021. The company highlighted progress in its clinical programs, including potential accelerated approval for INBRX-101 and orphan drug designation for INBRX-109.
Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company, announced its participation in several significant scientific conferences including the ACoP and SITC annual meetings. At ACoP (Oct 30-Nov 2, 2022), they will present a poster on INBRX-101 for Alpha-1 Antitrypsin Deficiency. The SITC (Nov 8-12, 2022) will showcase research on a targeted cytokine. Additionally, Inhibrx will present updates on INBRX-109 for chondrosarcoma at the CTOS meeting (Nov 16-19, 2022). Presentations will be accessible via their investor website.
Inhibrx, Inc. (Nasdaq: INBX) announced potential for accelerated approval from the FDA for INBRX-101, a recombinant human AAT-Fc fusion protein, aimed at treating emphysema due to alpha-1 antitrypsin deficiency (AATD). The FDA supports the use of functional AAT serum levels as a surrogate endpoint. All patients tested in the Phase 1 study showed detectable INBRX-101 in bronchoalveolar lavage fluid. Inhibrx plans to begin a registration-enabling trial in Q1 2023, with a recent amendment to its loan agreement enabling $30 million funding upon announcing this regulatory path.
Inhibrx, a clinical-stage biopharmaceutical company, will host a live webcast on October 4, 2022, at 5:30 a.m. PT, to discuss the regulatory pathway for INBRX-101. This treatment targets alpha-1 antitrypsin deficiency (AATD), a rare disease affecting about 100,000 patients in the U.S. INBRX-101 is designed for less frequent dosing compared to current therapies. The Phase 1 study demonstrated safety and efficacy, with no severe adverse events reported. The FDA granted INBRX-101 orphan-drug designation in March 2022.
Inhibrx, Inc. (Nasdaq: INBX) announced that the European Commission has granted orphan medicinal product designation to INBRX-109 for treating chondrosarcoma, building on a positive EMA opinion. This designation can lead to benefits like reduced fees and market exclusivity. Chondrosarcoma affects about 2,800 new patients annually in the US and EU, with no approved therapies currently available. INBRX-109 is a DR5 agonist antibody, and the company has initiated a Phase 2 trial, showing promising preliminary results in prior trials.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q2 2022 financial results with a net loss of $37.7 million ($0.97 per share), up from $20.7 million ($0.55 per share) in Q2 2021. The company had $176.4 million in cash and equivalents as of June 30, 2022. Key highlights include a successful Phase 1 trial of INBRX-101 for AAT deficiency and the completion of Phase 1 dose escalation for INBRX-105. The company secured $60 million from Oxford Finance through a loan agreement.